Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elagolix in Women With Polycystic Ovary Syndrome
NCT03951077Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2019
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of elagolix in polycystic ovary syndrome (PCOS) (6 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Menstrual Cycle Responders at Week 24. Started Aug 2019; status: completed.
02
Drugs
elagolix
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on NCT03951077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03951077.